Boston Scientific Announces Executive and Director Changes

Ticker: BSX · Form: 8-K · Filed: 2025-09-04T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, executive-compensation, board-of-directors

Related Tickers: BSX

TL;DR

BSX board shakeup and exec comp changes filed. Watch for new strategy.

AI Summary

Boston Scientific Corporation (BSX) announced on August 29, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and the election of new directors, alongside updates to compensatory plans for key executives. Specific details on the individuals involved and the financial implications of these compensation changes are outlined within the report.

Why It Matters

Changes in executive and director roles can signal shifts in company strategy or governance, potentially impacting future performance and investor confidence.

Risk Assessment

Risk Level: low — This filing primarily concerns corporate governance and executive compensation, which typically carries a lower immediate risk compared to financial distress or major operational disruptions.

Key Players & Entities

FAQ

What specific roles have been affected by the departure of certain officers?

The filing indicates departures of certain officers, but the specific roles are not detailed in the provided excerpt. Further review of the full document would be needed for specifics.

Who are the newly elected directors?

The filing mentions the election of directors, but their names are not provided in this excerpt. The full report would contain this information.

What are the key changes in compensatory arrangements for certain officers?

The filing states there are updates to compensatory arrangements for certain officers, but the details of these changes are not specified in the provided text.

What is the effective date of these reported changes?

The earliest event reported is dated August 29, 2025.

What is Boston Scientific Corporation's standard industrial classification?

Boston Scientific Corporation's standard industrial classification is SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841].

From the Filing

0000885725-25-000043.txt : 20250904 0000885725-25-000043.hdr.sgml : 20250904 20250904160743 ACCESSION NUMBER: 0000885725-25-000043 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250829 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250904 DATE AS OF CHANGE: 20250904 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 251293444 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 8-K 1 bsx-20250829.htm 8-K bsx-20250829 0000885725 false 0000885725 2025-08-29 2025-08-29 0000885725 us-gaap:CommonStockMember 2025-08-29 2025-08-29 0000885725 bsx:SeniorNotedue2027Member 2025-08-29 2025-08-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________________________________________________ Date of Report (Date of earliest event reported): August 29, 2025 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)      300 Boston Scientific Way , Marlborough , Massachusetts                  01752-1234     (Address of principal executive offices)                           (Zip Code) ( 508 ) 683-4000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.01 par value per share BSX New York Stock Exchange 0.625% Senior Notes due 2027 BSX27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company    ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 29, 2025, Jeffrey B. Mirviss informed Boston Scientific Co

View on Read The Filing